P3-079: Prospective evaluation of first-line tyrosine kinase inhibition with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene (FIELT study)  by De Gréve, Jacques L. et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS712
P3-079 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Prospective evaluation of first-line tyrosine kinase inhibition with 
erlotinib in patients with advanced non-small cell lung cancer 
(NSCLC) harbouring a mutant EGFR gene (FIELT study)
De Grève, Jacques L.1 Van Meerbeeck, Jan2 Vansteenkiste, Johan3 
Schallier, Denis4 Vermeij, Joanna5 Keppens, Carine4 Focan, Claude6 
Meert, Vanessa4 In ‘tveld, Peter4 Teugels, Erik4 
1 Medical Oncology, Oncologisch Centrum, UZBrussel, Brussels, 
Belgium 2 UZ Gent, Gent, Belgium 3 UZ Leuven, Leuven, Belgium 4 UZ 
Brussel, Brussels, Belgium 5 ZNA Antwerp, Antwerp, Belgium 6 CHC 
Liège, Liège, Belgium 
Background: EGFR gene tyrosine kinase (TK) domain mutations in-
crease sensitivity of the receptor both for the effects of ligand and small 
molecule tyrosine kinase inhibitors (TKI). Retrospective and limited 
prospective data have indicated impressive activity (response rate and 
response duration) in patients with advanced EGFR mutant lung cancer. 
The FIELT study is a single arm multicenter phase II study evaluating 
the safety and efﬁcacy of ﬁrst-line erlotinib in patients with advanced 
NSCLC with a documented EGFR mutation. 
Patients and Methods: Because of the anticipated low prevalence of 
EGFR mutations in Caucasian populations and the consequent large 
recruitment base needed, 24 clinical centers in Belgium and Luxem-
burg are cooperating in the trial. Patients are pre-selected on pheno-
type: adenocarcinoma with no or little smoking history. Diagnostic 
formalin-ﬁxed biopsy samples are analysed centrally for quality and 
proportion of tumor cells. Samples with > 25% tumor cells of any size 
are examined by DGGE and sequencing of exons 18-24 of the EGFR 
gene. In addition EGFR IHC and FISH are performed. Patients with a 
TK domain mutation in their tumor are then prospectively treated with 
erlotinib (150mg/day) until progression. The primary endpoint of the 
study is PFS at 3 months (hypothesis > 70%). Secondary endpoints are 
RECIST and early metabolic response, feasibility of this set-up and 
duration of response and survival. 
Results: Thus far, 36 patients have been screened for the presence of 
EGFR mutations. Nine patients had inconclusive mutation analysis 
(insufﬁcient tissue quality). An EGFR mutation was found in 9 (25%, 
34% of evaluable) cases, L858 (2cases) and del E746-A750 (7 cases) 
and 6 of these patients have initiated ﬁrst-line erlotinib treatment. All 
mutations were found in never-smokers.
Results of the mutation analysis were returned to the participating 
investigator within 2 weeks. IHC was positive in 26/31(84%) of cases 
and 10/30 (33%) had increased gene copy number. 
There was no association between EGFR copy number and mutation 
status.
Responses and response duration: 3 PR (12+w, 12+w, 9+w); 1SD 
(36+w). Two early progressions (both exon 19 deletions) occurred at 6 
w and 12 w. One patient subsequently responded dramatically to one 
cycle of platinum-based chemo, but expired due to massive haemopty-
sis. In this patient a novel additional (possible resistance) mutation was 
found in exon 21.
Conclusions: Pre-selection of NSCLC patients on phenotypic basis 
leads to a satisfactory mutation detection rate in EGFR. It is feasible 
to perform a mutation analysis before selecting ﬁrst-line treatment in a 
multicenter context, although diagnostic tissue samples are insufﬁcient 
in 25% of cases.
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Background: Erlotinib is the ﬁrst and only HER-1/EGFR tyrosine-
kinase inhibitor (TKI) that has shown survival beneﬁt in a ranzomized, 
placebo controlled trial. Although an exploratory analysis demonstrated 
that the clinical beneﬁt of Erlotinib in survival was observed across 
most patient subgroups, responses were more common in certain pa-
tients such as women, never smokers, or patients with adenocarcinoma 
histology. The purpose of the analysis we present here was to describe 
outcome in terms of response and survival in the group of men with 
NSCLC treated with Erlotinib in a phase II clinical trial.
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Pts. with histologically conﬁrmed stage IIIB or IV NSCLC who had 
received treatment with chemotherapy in second or third line as well 
as chemotherapy-naïve patients non suitable for ﬁrst line conventional 
chemotherapy were eligible. Eligibility criteria were: ≥18 years old, 
ECOG 0-2, adequate bone marrow, hepatic and renal function and 
written informed consent. Male patients receiving Erlotinib 150 mg/day 
p.o until disease progression or withdrawal were the subject of this 
analysis. 
Results: From April 2004 to March 2006, 1.796 pts were included 
in the TargeT trial, of those 1.108 male pts. were evaluated for this 
analysis. 96% of pts were active or former smokers; median age: 66 y 
(range 28-95); histology: 43% adenocarcinoma (including BAC), 32% 
squamous; 18% large cell carcinoma; 6% other; 81% exhibited stage 
IV carcinoma. ECOG PS 0/1/2 (%) 20/55/26. The % of pts receiving 
Erlotinib in 1st/2nd/3rd or further lines were: 24/39/37.
Among 606 patients with evaluable disease, overall response rate of 
11.1%, with 42.2% of stabilization of disease (control disease rate: 
54.3%) was reached. Response rate to Erlotinib was higher among 
patients with adenocarcinoma when compared with other histologies 
and those without smoking habit, although nonsmokers comprised only 
4% of the sample. No statistically signiﬁcant differences were found in 
these subgroups in terms of control disease rate (higher than 50% in all 
cases).
Median time to progression was 3.5 months (95% CI: 3.1-3.8). Both in 
the univariate and multivariate analysis, absence of smoking habit (7.0 
vs. 3.3 months) and performance status 0-1 (3.6 vs. 2.8 month) were 
associated with longer time to progression. No differences in TTP be-
tween adenocarcinoma and squamous histology were detected (hazard 
ratio: 0.86; 95% IC: 0.79-1.05). 
Median overall survival was 5.1 months (95% CI: 4.6-5.8). In the Cox 
regression analysis, performance status (0-1) was the only factor as-
sociated with longer survival (p<0.001). 
